8 completed, 7 recruiting, 7 unknown, 6 active not recruiting. 12 Phase 2, 4 Not applicable, 3 Phase 1, 3 Phase 3.
Follow PD-1 inhibitors: new trials by email Literature Review of PD-1 inhibitors trials Research Report on PD-1 inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma Pemigatinb, PD-1 inhibitors, Chemotherapy - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 154 | 2026-08-20 | 2026-08-26 |
| HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion HAIC, Lenvatinib, PD-1 Inhibitors - Hepatocellular Carcinoma (HCC) | Active not recruiting | Peking University | 150 | 2026-05-29 | 2026-06-09 | |
| Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma PD-1 Inhibitors - HCC, Adjuvant Therapy | Not yet recruiting | Tongji Hospital | 300 | 2026-01-31 | 2026-01-30 | |
| Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer Ivonescimab, PD-1 Inhibitors - Non-Small Cell Lung Cancer, Neoadjuvant Therapy | Recruiting | Peking University People's Hospital | 80 | 2025-07-01 | 2026-06-03 | |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
| Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer Posaconazole, Nab-paclitaxel, Carboplatin - Breast Cancer | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 72 | 2025-05-01 | 2026-02-25 |
| SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. SBRT, PD-1 Inhibitors, CapeOX + bevacizumab - Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 28 | 2025-02-01 | 2025-02-19 |
| TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma TACE, Lenvatinib, PD-1 Inhibitors - Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization | Not applicable | Recruiting | Sun Yat-sen University | 32 | 2024-12-13 | 2025-08-14 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 32 | 2024-07-20 | 2025-01-13 |
| The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients PD-1 Inhibitors - NSCLC | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 845 | 2024-07-08 | 2024-07-11 | |
| High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors - Colorectal Liver Metastases | Phase 1 | Unknown | Jiangsu Cancer Institute & Hospital | 30 | 2023-09-20 | 2023-09-21 |
| Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma Pemigatinib, PD-1 Inhibitors - Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2023-07-01 | 2023-06-22 |
| PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC PD-1 Inhibitors, Irinotecan, Capecitabine tablets - Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | Phase 3 | Unknown | Sun Yat-sen University | 380 | 2023-02-17 | 2024-01-23 |
| PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial PD-1 Antibody, BACE - NSCLC | Phase 2 / Phase 3 | Unknown | Xuhua Duan | 150 | 2022-10-29 | 2022-11-09 |
| Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma Lenvatinib, PD-1 inhibitors - Biliary Tract Cancer | Phase 2 | Unknown | The First Hospital of Jilin University | 46 | 2022-08-20 | 2022-09-10 |
| Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma PD-1 inhibitors, PD-1 and CTLA-4 inhibitors - Metastatic Malignant Melanoma | Not applicable | Active not recruiting | Institute of Oncology Ljubljana | 150 | 2022-03-01 | 2026-02-25 |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT HAIC, Lenvatinib 1, PD-1 Inhibitors - Hepatocellular Carcinoma, Portal Vein Thrombosis | Phase 2 | Completed | Peking University | 66 | 2022-01-10 | 2026-01-23 |
| Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. Low Dose Radiotherapy, stereotactic body radiation therapy, PD-1 Inhibitors - NSCLC, Low Dose Radiotherapy | Phase 1 | Active not recruiting | Sichuan University | 9 | 2021-12-15 | 2026-05-11 |
| Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors Methotrexate tablets, Anti-PD-1 monoclonal antibody, Radiotherapy - Solid Tumors | Phase 2 | Active not recruiting | Yancheng First People's Hospital | 50 | 2021-11-15 | 2024-10-26 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Hepatocellular (7) · Colorectal Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Neoplasm Metastasis (3) · Recurrence (3) · Biliary Tract Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Melanoma (2) · Breast Neoplasms (1) · Carcinoma (1) · Digestive System Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Lung Neoplasms (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Sun Yat-sen University (4) · Chen Xiaoping (2) · Ming-Yuan Chen (2) · Peking University (2) · BioNTech US Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fujian Medical University Union Hospital (1) · Haitao Zhao, MD (1) · Hunan Cancer Hospital (1) · Institute of Oncology Ljubljana (1) · Jiangsu Cancer Institute & Hospital (1) · Jiangxi Provincial Cancer Hospital (1) · Peking University People's Hospital (1) · Quanli Gao (1) · Shandong Cancer Hospital and Institute (1)
China (27) · Belgium (1) · Netherlands (1) · Slovenia (1)
Yunfei Yuan (2) · Chunxia Su, PHD (1) · Fan Yang (1) · Feng Duan, MD (1) · Lei Zhang, PHD (1) · Peirong Ding, M.D. (1) · Quanli Gao (1) · Shaoyuan Wang, Pro (1) · Shugeng Gao, MD (1) · WanGuang D Zhang (1) · Wei Geng, M.D. (1) · Xiaodong Wang (1) · Xiaodong Wang, MD (1)
PMID 37879536, PMID 38642937, PMID 39753970, PMID 40057343, PMID 40528044, PMID 41125109, PMID 41357510
2019 (1), 2023 (1)